Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
Biosimilars Regulatory Framework Must Evolve in Line with Emerging Scientific Evidence
Dr. Sundar Ramanan, Global Head of Regulatory Affairs, Biocon Biologics Dr. Sundar Ramanan, Vice President & Head, Global Regulatory Affairs, Biocon Biologics, presented on behalf of the Company at the public meeting for the reauthorization process for the Biosimilar User Fee Act (BsUFA III) program organized by the U.S. Food and Drug Administration (FDA) on … Continue reading Biosimilars Regulatory Framework Must Evolve in Line with Emerging Scientific Evidence
Expanding Oncology Portfolio for the Benefit of Cancer Patients
We added another feather in our cap with the U.S. FDA approval of Fulphila™, biosimilar Pegfilgrastim co-developed with our partner Mylan. Fulphila™ is the first FDA-approved biosimilar Pegfilgrastim and the second biosimilar from Biocon and Mylan’s joint portfolio approved in the U.S. Pegfilgrastim is a long-lasting, pegylated form of recombinant granulocyte colony-stimulating factor that is … Continue reading Expanding Oncology Portfolio for the Benefit of Cancer Patients
Biocon’s Trastuzumab Journey: First biosimilar from India to be approved by U.S. FDA
December 2017 was a defining moment in our biosimilars journey when Biocon and partner Mylan became the first companies globally to receive U.S. Food and Drug Administration (FDA) approval for biosimilar Trastuzumab. Ogivri™ (trastuzumab-dkst) was the first biosimilar from Mylan and Biocon’s joint portfolio approved in the U.S., and it made us the first Indian … Continue reading Biocon’s Trastuzumab Journey: First biosimilar from India to be approved by U.S. FDA
Biocon Presented PK-PD Data on Insulin Tregopil at American Diabetes Association, 78th Scientific Sessions – Suggesting an Oral Rapid Acting Insulin Option for Type 2 Diabetes Patients
Biocon recently presented data from its Insulin Tregopil clinical program at the American Diabetes Association’s (ADA) 78th Scientific Sessions held at Orlando, Florida, from 22nd to 26th June, 2018.
Biocon’s Landmark Achievement of First USFDA approval for Biosimilar Trastuzumab applauded by all including the Media
First Biosimilar Trastuzumab approved in the US
‘KRABEVA®’s Unique ‘Qual-Check’ Mechanism Ensures Patients Get a Quality-Ascertained Product’: Suresh Subramanian
Mr. Suresh Subramanian, Senior Vice President & Head Branded Formulations, Biocon shares his views on how KRABEVA® can make a significant impact in the biosimilars space.
Antimicrobial Resistance (AMR) – A global threat is here to stay!
Antimicrobial resistance (AMR) represents a global catastrophe that threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.
Personalized Medicine – Myth or Reality?
By Sreesha Srinivasa, PhD
Associate Vice President, Research and Development, Biocon Research Limited.
Antibodies as Drugs
By Narendra Chirmule, PhD
Senior VP & Head of Research and Development,
Biocon Research Limited.